松瑞藥 4167
OTC · Biotechnology and medical care19.25▲+0.25 (+1.32%)After close
- Prev close
- 19
- Volume (shares)
- 1,169,000
- Data time
- 2026-11-11 13:30:00
- Open
- 19.10
- High
- 19.35
- Low
- 18.75
- Prev close
- 19.00
- Volume (lots)
- 1,169
- Turnover
- 0.22 億
- P/E
- 5.8
- Cash yield
- 4.18%
Financial trends
Loading…
Consolidated statements; NT$100M (per-share items in NT$). Updated after each quarterly filing (MOPS). Some line items do not apply to financial companies.
Unit: 100 million TWD (EPS in TWD)Source: public data from MOPS, TWSE, TPEx and TDCC
Loading…
Figures are shown as announced, with no scoring or rating.
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 36.67% | 30.97% | 30.12% | 35.95% | 38.23% | 36.86% | 29.60% | 37.32% |
| Operating margin | 5.53% | 8.17% | 9.56% | 15.20% | 24.44% | 10.14% | 6.23% | 22.24% |
| Net margin | 270.21% | 38.62% | 27.24% | 27.99% | -5.27% | 145.96% | 16.53% | 12.62% |
| ROE (TTM) | 25.76% | 6.43% | 14.75% | 13.86% | 13.05% | 13.59% | 5.32% | 5.31% |
| ROA (TTM) | 22.23% | 5.45% | 12.47% | 12.42% | 11.38% | 12.14% | 4.35% | 4.66% |
| EPS, quarter (TWD) | 2.31 | 0.29 | 0.29 | 0.26 | -0.05 | 1.22 | 0.14 | 0.14 |
| EPS, TTM (TWD) | 3.15 | 0.79 | 1.72 | 1.57 | 1.45 | 1.57 | 0.57 | 0.56 |
| Month | Revenue | MoM | YoY | YTD | YTD YoY |
|---|---|---|---|---|---|
| 2026-10 | 1.4 | 30.84% | 21.29% | 9.7 | -1.98% |
| 2026-09 | 1.0 | -11.17% | 33.74% | 8.4 | -4.94% |
| 2026-08 | 1.2 | 20.20% | 22.30% | 7.3 | -8.68% |
| 2026-07 | 1.0 | -4.68% | -10.44% | 6.2 | -12.88% |
| 2026-06 | 1.0 | 16.23% | -0.18% | 5.2 | -13.32% |
| 2026-05 | 0.9 | -8.05% | -23.04% | 4.2 | -16.03% |
| 2026-04 | 1.0 | 12.11% | -19.39% | 3.3 | -13.93% |
| 2026-03 | 0.9 | 32.60% | -9.07% | 2.3 | -11.48% |
| 2026-02 | 0.6 | -23.25% | -10.87% | 1.5 | -12.80% |
| 2026-01 | 0.8 | -29.96% | -14.23% | 0.8 | -14.23% |
| 2025-12 | 1.2 | 36.28% | 106.67% | 12.0 | -1.28% |
| 2025-11 | 0.9 | -21.75% | -23.77% | 10.8 | -6.68% |
Revenue in NT$100M; 12 months per page.
| Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.9 | 2.3 | 3.2 | 2.8 | 3.4 | 2.6 | 2.8 | 3.3 |
| Cost of revenue | 1.8 | 1.6 | 2.2 | 1.8 | 2.1 | 1.7 | 1.9 | 2.1 |
| Gross profit | 1.0 | 0.7 | 1.0 | 1.0 | 1.3 | 1.0 | 0.8 | 1.2 |
| Operating expenses | 0.9 | 0.5 | 0.7 | 0.6 | 0.5 | 0.7 | 0.6 | 0.5 |
| Operating income | 0.2 | 0.2 | 0.3 | 0.4 | 0.8 | 0.3 | 0.2 | 0.7 |
| Non-operating items | 7.7 | 0.7 | 0.6 | 0.4 | -1.0 | 3.6 | 0.3 | -0.3 |
| Pre-tax income | 7.8 | 0.9 | 0.9 | 0.8 | -0.2 | 3.9 | 0.5 | 0.4 |
| Continuing operations | 7.7 | 0.9 | 0.9 | 0.8 | -0.2 | 3.9 | 0.5 | 0.4 |
| Net income | 7.7 | 0.9 | 0.9 | 0.8 | -0.2 | 3.9 | 0.5 | 0.4 |
| Net income to parent | 7.7 | 0.9 | 0.9 | 0.8 | -0.2 | 3.9 | 0.5 | 0.4 |
| Net income to NCI | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 | -0.0 |
| Total comprehensive income | 7.7 | 0.9 | 0.9 | 0.8 | -0.2 | 3.9 | 0.5 | 0.4 |
| EPS (TWD) | 2.31 | 0.29 | 0.29 | 0.26 | -0.05 | 1.22 | 0.14 | 0.14 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Current assets | 36.5 | 28.5 | 25.6 | 26.0 | 27.6 | 30.9 | 32.5 | 25.7 |
| Non-current assets | 15.2 | 16.7 | 16.3 | 15.1 | 13.3 | 11.6 | 11.3 | 12.4 |
| Total assets | 51.6 | 45.2 | 41.8 | 41.1 | 40.9 | 42.4 | 43.8 | 38.1 |
| Current liabilities | 5.9 | 7.2 | 2.3 | 2.5 | 3.1 | 1.7 | 6.9 | 1.4 |
| Non-current liabilities | 1.8 | 1.8 | 1.7 | 1.7 | 1.7 | 1.7 | 1.7 | 2.0 |
| Total liabilities | 7.7 | 9.0 | 4.0 | 4.2 | 4.8 | 3.4 | 8.6 | 3.4 |
| Share capital | 33.2 | 31.0 | 31.0 | 31.0 | 31.7 | 31.7 | 31.7 | 31.7 |
| Capital surplus | 1.3 | 1.3 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 |
| Retained earnings | 9.4 | 3.8 | 5.4 | 4.5 | 4.4 | 5.9 | 2.0 | 1.5 |
| Other equity | 0.0 | — | — | — | — | — | — | — |
| Treasury stock | 0.0 | — | 0.0 | 0.0 | -1.4 | — | — | — |
| Equity to parent | 43.9 | 36.2 | 37.8 | 36.9 | 36.1 | 38.9 | 35.1 | 34.6 |
| Non-controlling interests | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 |
| Total equity | 43.9 | 36.2 | 37.8 | 36.9 | 36.1 | 39.0 | 35.2 | 34.7 |
| Book value per share (TWD) | 14.15 | 11.66 | 12.18 | 11.89 | 11.63 | 12.27 | 11.05 | 10.91 |
Amounts in NT$100M (per-share items in NT$).
| Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.3 | -3.0 | -1.0 | 1.0 | -0.5 | 0.3 | 1.4 | 1.2 |
| Investing cash flow | 4.5 | 0.4 | -4.3 | 2.7 | -2.3 | 1.6 | 0.2 | -2.0 |
| Financing cash flow | -1.9 | 2.9 | -0.0 | -1.3 | -1.4 | -0.0 | -0.0 | -0.3 |
| Net change in cash | 1.3 | 0.3 | -5.3 | 2.4 | -4.3 | 1.8 | 1.6 | -1.1 |
| Cash, beginning | 8.2 | 8.2 | 13.6 | 13.6 | 13.6 | 13.6 | 10.8 | 10.8 |
| Cash, ending | 9.8 | 8.5 | 8.2 | 13.6 | 11.2 | 15.4 | 13.6 | 11.9 |
Amounts in NT$100M (per-share items in NT$).
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Current ratio | 623.23% | — | — | — | — | — | — | — |
| Debt ratio | 14.89% | 19.95% | 9.64% | 10.21% | 11.72% | 8.06% | 19.65% | 8.99% |
| Equity ratio | 85.11% | 80.05% | 90.36% | 89.79% | 88.28% | 91.94% | 80.35% | 91.01% |
| Equity multiplier | 1.17 | 1.25 | 1.11 | 1.11 | 1.13 | 1.09 | 1.24 | 1.10 |
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|
| Asset turnover (TTM revenue / avg. assets) | 0.24 | 0.27 | 0.28 | 0.29 | 0.30 | 0.30 | 0.30 | 0.33 |
| Equity turnover | 0.28 | 0.31 | 0.33 | 0.32 | 0.34 | 0.33 | 0.35 | 0.37 |
Source: MOPS. For reference only; not investment advice.